NLS Pharmaceutics AG
NLSP
$1.47
-$0.053-3.48%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.60M | -9.38M | -12.17M | -13.82M | -15.47M |
| Total Depreciation and Amortization | 11.60K | 11.60K | 11.60K | 11.60K | 11.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | 33.50K | 67.00K |
| Total Other Non-Cash Items | 278.80K | 251.60K | 224.40K | 595.80K | 967.20K |
| Change in Net Operating Assets | 2.39M | 2.32M | 2.25M | 1.58M | 911.40K |
| Cash from Operations | -3.92M | -6.80M | -9.68M | -11.60M | -13.51M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.63M | 1.63M | 1.63M | 1.58M | 1.53M |
| Total Debt Repaid | -194.80K | -97.40K | -- | -177.20K | -354.40K |
| Issuance of Common Stock | 1.38M | 690.10K | -- | 3.65M | 7.30M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 2.67M | 5.33M |
| Cash from Financing | 2.82M | 2.23M | 1.63M | 7.72M | 13.81M |
| Foreign Exchange rate Adjustments | 400.00 | 200.00 | 0.00 | -400.00 | -800.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.10M | -4.57M | -8.05M | -3.88M | 297.20K |